Human trials begin of Sanofi and Translate Bio’s Covid-19 vaccine candidate
It is the latest vaccine candidate based on messenger RNA, after jabs by Pfizer-BioNTech and Moderna were launched when clinical trials showed high efficacy rates
12 March 2021 - 09:51
Paris — Sanofi and Translate Bio said on Friday they had started a human trial of their mRNA Covid-19 vaccine candidate, the French drugmaker’s second vaccine project, which follows a protein-based shot hit by a delay in 2020.
It is the latest vaccine candidate based on a new technology known as messenger RNA. Shots by Pfizer-BioNTech and Moderna were launched after clinical trials showed high efficacy rates...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.